{
    "clinical_study": {
        "@rank": "62077", 
        "arm_group": {
            "arm_group_label": "LJM716", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate safety and tolerability to estimate the MTDand/or recommended dose."
        }, 
        "brief_title": "A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Neoplasms", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This is a phase I, open-label, dose-escalation study to establish the MTD and/or RDE of\n      LJM716 as single agent in Japanese patients that have advanced solid tumors. The study\n      consists of a dose escalation part and a dose expansion part."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients with the following indications:\n\n             i) (Dose escalation part only): HER2 overexpressing locally advanced/ metastatic\n             breast cancer or gastric cancer for which no effective treatment option exists:\n\n               -  For breast cancer: documented 3+ by immunohistochemistry, or amplification by in\n                  situ hybridization\n\n               -  For gastric cancer (including GE junction tumors): documented 3+ by\n                  immunohistochemistry, or 2+ by immunohistochemistry and amplification by in situ\n                  hybridization OR, ii) (Dose escalation part only): Recurrent or metastatic SCCHN\n                  regardless of HER2 status for which no effective treatment option exists OR,\n                  iii) Recurrent or metastatic ESCC regardless of HER2 status for which no\n                  effective treatment option exists\n\n          2. ECOG Performance Status of 0-2\n\n          3. Must have recovered from the adverse effects of any prior surgery, radiotherapy or\n             other antineoplastic therapy. Alopecia and CTCAE Grade 1 peripheral neuropathy is\n             acceptable.\n\n          4. Willingness and ability to comply with all study procedures\n\n          5. Written informed consent obtained prior to any screening procedures\n\n          6. During dose expansion part of the study, patients must have at least one measurable\n             lesion as defined by RECIST v1.1 criteria"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01911936", 
            "org_study_id": "CLJM716X1101"
        }, 
        "intervention": {
            "arm_group_label": "LJM716", 
            "intervention_name": "LM716", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "CLJM716,", 
            "Japanese patients,", 
            "Neoplasms"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sunto-gun", 
                        "country": "Japan", 
                        "state": "Shizuoka", 
                        "zip": "411-8777"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Koto", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "135-8550"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka", 
                        "country": "Japan", 
                        "zip": "811-1395"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+81337978748"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency (PMDA)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of dose-limiting toxicities (DLTs) in the dose escalation part", 
            "safety_issue": "Yes", 
            "time_frame": "First cycle (28 days)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01911936"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Frequency and severity of adverse events, number of and reasons for", 
                "safety_issue": "Yes", 
                "time_frame": "from informed consent till 30 days after end of treatment"
            }, 
            {
                "measure": "LJM716 serum concentration-time- profile and estimated PK", 
                "safety_issue": "No", 
                "time_frame": "up to 10 cycle  (1 cycle = 28 days)"
            }, 
            {
                "measure": "Tumor response according to RECIST 1.1", 
                "safety_issue": "No", 
                "time_frame": "every 2 months until end of treatment up to 2 years"
            }, 
            {
                "measure": "Incidence of antibodies against LJM716", 
                "safety_issue": "No", 
                "time_frame": "up to 10 cycle ( 1cycle = 28 days)"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}